Frontlight ResearchEarly access
Not yet taking people in CzechiaPhase 2
Lower Versus Standard Blood Thinner Doses During ECMO for Heart or Lung Failure
Compares lower and standard doses of argatroban or enoxaparin in adults on ECMO.
Key facts
- Who runs it
- Fakultni Nemocnice Ostrava
- Where
- Ostrava and Prague, CzechiaSee the 2 sites
- Trial code
- Registry title
- Low-dose versus standard-dose anticoagulation with argatroban or enoxaparin during extracorporeal membrane oxygenation controlled by anti-IIa or anti-Xa assay
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 200 people, planned
- Started
- 2 Mar 2026
- Expected to end
- 29 Feb 2028
- Type of study
- Interventional
- Record updated
- 19 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are on ECMO (a machine that supports the heart and lungs) and receive argatroban or enoxaparin to prevent blood clots.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Earlier treatment
- People must be on ECMO support with argatroban or enoxaparin anticoagulation.
Main reasons for not taking part
- Included in the lung transplant program at Motol Hospital
- Known hypersensitivity to components of the investigational medicinal products
- Allergic reaction to the active substances of the investigational medicinal products
- Pregnancy
- Breastfeeding
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- ECMO support with argatroban / enoxaparin anticoagulation
- Age ≥ 18 years
- Obtaining informed consent according to the procedure specified in the protocol
Who cannot take part
- Inclusion in the lung transplant program at Motol Hospital
- Known hypersensitivity to components of the investigational medicinal products
- Allergic reaction to the active substances of the investigational medicinal products
- Pregnancy and breastfeeding
Where in Czechia
- Fakultni nemocnice OstravaOstrava, CzechiaNot yet recruiting
- Fakultni nemocnice v MotolePrague, CzechiaNot yet recruiting
About the trial
What the trial wants to find out
Description of the efficacy and safety of low dose (LD) and standard dose (SD) anticoagulation with argatroban and enoxaparin in patients on ECMO support.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Low-dose versus standard-dose anticoagulation with argatroban or enoxaparin during extracorporeal membrane oxygenation controlled by anti-IIa or anti-Xa assay
- Plain-language title
- Lower Versus Standard Blood Thinner Doses During ECMO for Heart or Lung FailureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 19 March 2026